Erasca, Inc.(ERAS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ERAS Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Erasca, Inc. (ERAS), a Healthcare sector company. ERAS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Erasca, Inc. reports net income of $-44.1M, free cash flow of $-27.3M. Top institutional holders of ERAS by reported 13-F value include Frazier Life Sciences Management, L.P., T. Rowe Price Investment Management, BlackRock, based on the most recent SEC filings. ERAS trades on the Nasdaq exchange and files with the SEC under CIK 1761918. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ERAS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Erasca, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-44.1M
Free Cash Flow
Q2 2026
$-27.3M
ROIC
Q2 2026
-52.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+23.0% YoYOperating Income
+21.5% YoYEPS (Diluted)
+36.2% YoYTotal Assets
-21.2% YoYOp. Cash Flow
+12.8% YoYFree Cash Flow
+12.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-124.5M +23.0% | $-161.7M -29.3% | $-125.0M +48.5% | $-242.8M -97.8% | $-122.8M -20.8% | $-101.7M |
| Operating Income | $-140.9M +21.5% | $-179.6M -26.9% | $-141.5M +42.8% | $-247.4M -98.1% | $-124.9M -14.3% | $-109.3M |
| EPS (Diluted) | $-0.44 +36.2% | $-0.69 +16.9% | $-0.83 +58.3% | $-1.99 -7.6% | $-1.85 | — |
| Total Assets | $396.2M -21.2% | $502.5M +27.1% | $395.3M -23.2% | $514.9M +2.7% | $501.4M +301.7% | $124.8M |
| Operating Cash Flow | $-95.5M +12.8% | $-109.4M -8.1% | $-101.2M +2.0% | $-103.3M -29.7% | $-79.6M -143.5% | $-32.7M |
| Free Cash Flow | $-95.6M +12.7% | $-109.5M -6.3% | $-103.0M +12.6% | $-117.8M -29.7% | $-90.8M -170.0% | $-33.6M |
Get alerted when ERAS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Erasca, Inc. including:
Top Institutional Holders of ERAS
Frazier Life Sciences Management, L.P.
$457.5M24,975,188 shT. Rowe Price Investment Management, Inc.
$388.1M21,185,839 shBlackRock, Inc.
$387.5M21,154,146 shRTW INVESTMENTS, LP
$328.8M17,946,754 shVR Adviser, LLC
$327.8M17,891,812 shSTATE STREET CORP
$223.2M12,184,555 shLogos Global Management LP
$222.6M12,150,000 shVANGUARD CAPITAL MANAGEMENT LLC
$208.9M11,402,199 shSiren, L.L.C.
$208.8M11,397,781 shParadigm Biocapital Advisors LP
$175.0M9,550,000 sh
| Fund | Value | Shares |
|---|---|---|
| Frazier Life Sciences Management, L.P. | $457.5M | 24,975,188 |
| T. Rowe Price Investment Management, Inc. | $388.1M | 21,185,839 |
| BlackRock, Inc. | $387.5M | 21,154,146 |
| RTW INVESTMENTS, LP | $328.8M | 17,946,754 |
| VR Adviser, LLC | $327.8M | 17,891,812 |
| STATE STREET CORP | $223.2M | 12,184,555 |
| Logos Global Management LP | $222.6M | 12,150,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $208.9M | 11,402,199 |
| Siren, L.L.C. | $208.8M | 11,397,781 |
| Paradigm Biocapital Advisors LP | $175.0M | 9,550,000 |
More Healthcare Companies
View all Healthcare →Put ERAS on your watchlist
Track score changes the day Erasca, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ERAS a good stock to buy?
13F Pro's AI-powered analysis of Erasca, Inc. (ERAS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ERAS are available on the ERAS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ERAS is classified as a mid company.
Which hedge funds own ERAS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ERAS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Erasca, Inc.'s investment landscape.